ATE210943T1 - Ophthalmologisches abgabesystem - Google Patents

Ophthalmologisches abgabesystem

Info

Publication number
ATE210943T1
ATE210943T1 AT95923983T AT95923983T ATE210943T1 AT E210943 T1 ATE210943 T1 AT E210943T1 AT 95923983 T AT95923983 T AT 95923983T AT 95923983 T AT95923983 T AT 95923983T AT E210943 T1 ATE210943 T1 AT E210943T1
Authority
AT
Austria
Prior art keywords
ophthalmological
delivery system
delivery
formulations
alginate
Prior art date
Application number
AT95923983T
Other languages
English (en)
Inventor
Smadar Cohen
Esther Lobel
Original Assignee
Teva Pharma
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Univ Ben Gurion filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE210943T1 publication Critical patent/ATE210943T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT95923983T 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem ATE210943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26229494A 1994-06-20 1994-06-20
PCT/US1995/007789 WO1995035073A1 (en) 1994-06-20 1995-06-19 Ophthalmic delivery system

Publications (1)

Publication Number Publication Date
ATE210943T1 true ATE210943T1 (de) 2002-01-15

Family

ID=22996942

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923983T ATE210943T1 (de) 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem

Country Status (6)

Country Link
US (1) US5776445A (de)
EP (1) EP0777451B1 (de)
AT (1) ATE210943T1 (de)
DE (1) DE69524772D1 (de)
IL (1) IL114193A (de)
WO (1) WO1995035073A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106819A (en) * 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
FR2777189B1 (fr) * 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
FR2779953B1 (fr) * 1998-06-22 2000-08-11 Codif International Sa Procede d'elaboration d'un produit cosmetique destine a proteger la peau contre les agressions resultant de la pollution de l'air ambiant
US6730691B1 (en) * 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003072081A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
EP2130541A3 (de) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Verfahren zur Behandlung oder Vorbeugung von Autoimmunerkrankungen mit 2,4-Pyrimidindiaminverbindungen
EP1620140B1 (de) 2003-05-05 2013-10-09 Ben-Gurion University Of The Negev Research And Development Authority Injizierbare vernetzte polymere zusammensetzungen und deren verwendungen
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
EP1756272A2 (de) * 2004-01-09 2007-02-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verbindungen, pharmazeutische zusammensetzungen und therapieverfahren zur vorbeugung und behandlung von mit amyloidfibrillenbildung assoziierten krankheiten und störungen
DE602005015936D1 (de) * 2004-02-26 2009-09-24 Bausch & Lomb Viskoelastische alginat-zusammensetzung, herstellungsverfahren und verpackung
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
WO2007005421A2 (en) * 2005-07-01 2007-01-11 Bausch & Lomb Incorporated Long lasting alginate dry eye, related methods of manufacture and methods of use
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
EP2420505A1 (de) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug-Salze von 2,4-Pyrimidindiaminverbindungen und Anwendungen davon
WO2008088612A1 (en) * 2006-12-20 2008-07-24 Bausch & Lomb Incorporated Method of stimulating the production of mucin in the eye of a patient
US20080153908A1 (en) * 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
WO2008082948A2 (en) * 2006-12-29 2008-07-10 Bausch & Lomb Incorporated Ophthalmic alginate composition related methods of manufacture and methods of use
WO2008137496A1 (en) * 2007-05-04 2008-11-13 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
US20080280853A1 (en) * 2007-05-07 2008-11-13 Erning Xia Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20110046033A1 (en) * 2008-01-31 2011-02-24 Jinzhong Zhang Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
US9096819B2 (en) 2008-01-31 2015-08-04 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
US9481856B2 (en) * 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
AU2009256553A1 (en) * 2008-06-12 2009-12-17 Novartis Ag In situ gelling systems as sustained delivery for front of eye
US20110195927A1 (en) * 2008-09-15 2011-08-11 Compositions Comprising Polymers Having Aminio Sugar Unites And Methods Of Making And Using Same Compositions Comprising Polymers Having Amino Sugar Units and Methods of Making and Using Same
US20100087550A1 (en) 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
EP2565193B1 (de) 2009-01-23 2014-03-19 Rigel Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung des JAK-Signalwegs
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
CN102395401B (zh) 2009-02-12 2015-08-19 因赛普特有限责任公司 经由水凝胶塞的药物递送
KR101740076B1 (ko) 2009-07-28 2017-06-08 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
SI2563771T1 (sl) 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
CA2804199C (en) 2010-07-28 2020-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN105078973B (zh) 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2011326487B2 (en) 2010-11-13 2017-03-02 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2011343966B2 (en) 2010-12-13 2017-03-16 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
WO2012116254A2 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
US8883497B2 (en) 2011-04-28 2014-11-11 University Of Southern California Human myeloid derived suppressor cell cancer markers
US8901121B2 (en) 2011-06-19 2014-12-02 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
BR122020013521B1 (pt) 2011-06-19 2021-05-25 Viamet Pharmaceuticals (NC), Inc compostos inibidores de metaloenzima
JP6223329B2 (ja) 2011-06-23 2017-11-01 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素化合物
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
EP2788343B1 (de) 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzymhemmerverbindungen
JP6189865B2 (ja) 2012-01-20 2017-08-30 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害薬化合物
JP6231548B2 (ja) 2012-03-23 2017-11-15 マテオン セラピューティクス， インコーポレイテッド カテプシンの阻害のための組成物および方法
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
BR112015031253B1 (pt) 2013-06-13 2021-09-28 Orgenesis Ltd. Método para produção de uma população de células transdiferenciada
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3872069A1 (de) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmazeutische zusammensetzungen mit perillylalkoholderivaten
JP2018515529A (ja) 2015-05-12 2018-06-14 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ ハイドロゲルからの薬物送達
CA2993661A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物
CA3028997A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
EP3532465B1 (de) 2016-10-26 2023-03-01 Rigel Pharmaceuticals, Inc. Pyrazolamidverbindungen als irak-inhibitoren
DK3532470T3 (da) 2016-10-26 2023-02-20 Rigel Pharmaceuticals Inc Oxazolderivater til anvendelse som irak-hæmmere og fremgangsmåde til fremstilling deraf
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
EP3562306B1 (de) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
EP3562487B1 (de) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
EP3635106A4 (de) 2017-05-08 2021-01-06 Orgenesis Ltd. Transdifferenzierte zellpopulationen und verfahren zur verwendung davon
JP7167069B2 (ja) 2017-06-29 2022-11-08 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害剤ならびに作製および使用のための方法
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
CN119868317A (zh) 2018-02-08 2025-04-25 南加州大学 穿透血脑屏障的方法
IL278416B2 (en) 2018-05-03 2023-12-01 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for their preparation and use
PE20211383A1 (es) 2018-05-03 2021-07-27 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US12358893B2 (en) 2019-01-08 2025-07-15 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
AU2020335903A1 (en) 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
HRP20251589T1 (hr) 2019-11-07 2026-01-30 Rigel Pharmaceuticals, Inc. Heterociklični spojevi koji inhibiraju rip1
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
US12459941B2 (en) 2022-03-31 2025-11-04 Rigel Pharmaceuticals, Inc. Tricyclic IRAK inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
IT1203814B (it) * 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
WO1989008446A1 (fr) * 1988-03-09 1989-09-21 Snow Brand Milk Products Co., Ltd. Preparation a liberation freinee preparee grace a l'utilisation d'acide alginique
FR2645439B1 (fr) * 1989-04-07 1991-06-21 Oreal Procede de preparation de capsules d'alginate(s) particulierement adaptees a un usage cosmetique, appareil pour sa mise en oeuvre et composition cosmetique contenant lesdites capsules
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物

Also Published As

Publication number Publication date
EP0777451B1 (de) 2001-12-19
IL114193A (en) 2000-02-29
DE69524772D1 (de) 2002-01-31
WO1995035073A1 (en) 1995-12-28
EP0777451A4 (de) 1998-06-10
EP0777451A1 (de) 1997-06-11
US5776445A (en) 1998-07-07
IL114193A0 (en) 1995-10-31

Similar Documents

Publication Publication Date Title
ATE210943T1 (de) Ophthalmologisches abgabesystem
BR0014203A (pt) Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
AU6185398A (en) Charged lipids and uses for the same
FI970788A0 (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DE69728678D1 (de) Hydrokolloid-wundgel
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
EP0693281A3 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
NO954320L (no) Lyosfærer omfattende gonadotropin
DK0759687T3 (da) Anvendelse af gelpræparater som bejdsemidler
DE60016798D1 (de) Papiertuch enthaltend antivirale wirkstoffe die hautfreundlich sind
TW327602B (en) A pharmaceutical composition of an ophthalmic suspension containing difluprednate
AR004168A1 (es) Composicion farmaceutica liquida vertible acuosa
ATE240094T1 (de) Ophthalmische zusammensetzungen in form wässriger gele
PT727996E (pt) Formulacoes de febbendazol
ATE272389T1 (de) Verwendung einer lacrophyl zubereitung in augentropfen, die therapeutisch wirksame komponenten enthalten
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
SE9403905D0 (sv) New formulations
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
SE9302203D0 (sv) Composition for ophthalmic use
KR950700685A (ko) 최음제로서 사용되는 요드화수소산(use of hydriodic acid as an aphrodisiac)
ES512751A0 (es) "procedimiento para la preparacion de un colirio antiseptico para afecciones oculares".
ES2132642T3 (es) Concentrados acuosos para suspension de endosulfan.
UA29890C2 (uk) Краплі для очей "вінісан"
MX9600140A (es) Uso de derivados de tocoferilo de vitamina e en composiciones oftalmicas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties